MindMed Rebrands to Definium Therapeutics, with Three Phase 3 Readouts Expected in 2026 for DT120 ODT in GAD and MDD

Definium Therapeutics rebrands from Mind Medicine (MindMed) and frames the change as a step toward evidence-driven psychiatry, applying scientific rigor to psychedelics. The company highlights a late-stage pipeline anchored by DT120 orally disintegrating tablet (ODT). Three Phase 3 topline readouts are expected in 2026: Voyage (2Q 2026) and Panorama (2H 2026) for DT120 ODT in generalized anxiety disorder (GAD), plus Emerge (mid-year 2026) in major depressive disorder (MDD). It also plans to initiate Ascend (second MDD Phase 3 study) in mid-year 2026. DT120 ODT has FDA Breakthrough Therapy Designation for GAD, and Definium says it is preparing commercialization and forward clinical development while continuing early-stage work including first-patient dosing in a Phase 2a study of DT402 in adults with autism spectrum disorder (ASD). The Nasdaq ticker symbol will change to DFTX effective January 13, 2026.